Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018019048) COMPOSITION CONTAINING LUTEIN/LUTEIN ESTER AND APPLICATIONS THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/019048 International Application No.: PCT/CN2017/088229
Publication Date: 01.02.2018 International Filing Date: 14.06.2017
Chapter 2 Demand Filed: 12.02.2018
IPC:
A61K 31/047 (2006.01) ,A61K 31/23 (2006.01) ,A61K 31/015 (2006.01) ,A61P 27/02 (2006.01) ,A61P 27/10 (2006.01) ,A61P 27/12 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
045
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
047
having two or more hydroxy groups, e.g. sorbitol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
22
of acyclic acids, e.g. pravastatin
23
of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
01
Hydrocarbons
015
carbocyclic
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
10
for accommodation disorders, e.g. myopia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
12
for cataracts
Applicants:
上海宣泰生物科技有限公司 SINONUTRACEUTICAL CO., LTD. [CN/CN]; 中国上海市 浦东新区海科路99号3号楼1楼 1st Flr., Bldg.3 99 Haike Road, Pudong New District Shanghai 201210, CN
Inventors:
顾茂健 GU, Maojian; CN
苏健梅 SU, Jianmei; CN
Agent:
上海光华专利事务所 J.Z.M.C. PATENT AND TRADEMARK LAW OFFICE; 中国上海市 杨浦区国定路335号5022室余明伟 YU, Mingwei Room5022 No.335, Guo Ding Road, Yangpu District Shanghai 200433, CN
Priority Data:
201610600364227.07.2016CN
Title (EN) COMPOSITION CONTAINING LUTEIN/LUTEIN ESTER AND APPLICATIONS THEREOF
(FR) COMPOSITION CONTENANT DE LA LUTÉINE/UN ESTER DE LUTÉINE ET SES APPLICATIONS
(ZH) 含有叶黄素/叶黄素酯的组合物及其应用
Abstract:
(EN) Disclosed in the present invention are a composition containing lutein/lutein ester and applications thereof. Components of the composition containing lutein/lutein ester comprise lutein/lutein ester, β-carotene and a pharmaceutically acceptable carrier. The weight ratio of lutein/lutein ester to β-carotene is 1: 0.1-100. In the present invention, by cooperatively using lutein/lutein ester and β-carotene and using auxiliary natural healthy ingredients, the dosage form of an orally disintegrating tablet is prepared. The orally disintegrating tablet is absorbed through the oral cavity, has fast effectiveness and small first-pass effect, reduces damage of gastric acid to lutein/lutein ester, has high bioavailability, and has the characteristics of nutritional and health-care effects, good mouthfeel and fast absorption. By eating the product, visual power can be obviously enhanced, the ocular blood flow is increased, and eye muscle fatigue is alleviated, and accordingly the morbidities of cataract, senile niacula lutea retinae lesion and adolescent myopia are reduced.
(FR) La présente invention concerne une composition contenant de la lutéine/un ester de lutéine et ses applications. Les composants de la composition contenant de la lutéine/de l'ester de lutéine comprennent de la lutéine/de l'ester de lutéine, du beta-carotène et un excipient pharmaceutiquement acceptable. Le rapport en poids de la lutéine/l'ester de lutéine au β-carotène est de 1 : 0,1 à 100. Dans la présente invention, en utilisant de façon coopérative la lutéine/l'ester de lutéine et le β-carotène et en utilisant des composants auxiliaires de santé naturels, la forme pharmaceutique d'un comprimé à désintégration orale est préparée. Le comprimé à désintégration orale est absorbé par l'intermédiaire de la cavité buccale, présente une efficacité rapide et un effet de premier passage faible, réduit la dégradation de la lutéine/l'ester de lutéine causée par l'acide gastrique, présente une biodisponibilité élevée, et présente les caractéristiques d'effets nutritionnels et de soins de santé, une bonne sensation en bouche et une absorption rapide. En consommant le produit, la puissance visuelle peut être clairement améliorée, la circulation sanguine oculaire est augmentée et la fatigue des muscles oculaires est atténuée, et en conséquence, les morbidités de cataracte, lésion rétinienne de macula lutea sénile et myopie de l'adolescent sont réduites.
(ZH) 本发明公开了一种含有叶黄素/叶黄素酯的组合物及其应用,含有叶黄素/叶黄素酯的组合物,其组成包括叶黄素/叶黄素酯和β-胡萝卜素以及医药学上可接受的载体,叶黄素/叶黄素酯与β-胡萝卜素的重量比为1∶0.1~100。本发明将叶黄素/叶黄素酯和β-胡萝卜素协同使用,辅以天然健康配料,做成口崩片的剂型,经口腔吸收,起效快,首过效应小,减少了胃酸对叶黄素/叶黄素酯的破坏作用,生物利用度高,使之既有营养保健的作用又具有口感好、吸收快的特性。食用本品,可明显提高视觉能力,增加眼球血流量、改善眼部肌肉疲劳,进而降低白内障、老年性视网膜黄斑病变、青少年近视发病率。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)